Status:

COMPLETED

A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza

Lead Sponsor:

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Conditions:

Influenza

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

Analyse the time of flu symptom relief in adults with uncomplicated acute influenza,to evaluate the antiviral effects of high and low doses of GP681 tablets, and explore the optimal dose for phase III...

Eligibility Criteria

Inclusion

  • Positive Influenza rapid antigen test;
  • Fever (axillary temperature ≥37.3℃) or the axillary temperature ≥37.3℃ after taking the medicine for more than 4 hours;
  • At least one systemic symptom and respiratory symptom related to a moderate or above influenza virus infection:
  • Systemic symptoms: headache, fever or chills, muscle or joint aches, fatigue;
  • Respiratory system symptoms: cough, sore throat, nasal congestion.
  • Time of disease symptoms ≤48h

Exclusion

  • Diagnosed as severe influenza patient ;
  • Known history of dysphagia or any gastrointestinal disease that affects drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, stomach After subtotal resection, etc.);
  • Have used anti-influenza virus drugs (oseltamivir, zanamivir, peramivir, favipiravir, abidol, baloxavir dipivoxil, amantadine, or diamond) within 2 weeks before screening Ethylamine, etc.);
  • Acute respiratory infections, otitis media, sinusitis or other infectious diseases such as bronchitis, pneumonia, tuberculosis, etc. occurred within 2 weeks before screening, and are in the acute stage;
  • Patients who also suffer from bacterial or viral infections and need systemic antibacterial or antiviral therapy

Key Trial Info

Start Date :

January 8 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 18 2021

Estimated Enrollment :

216 Patients enrolled

Trial Details

Trial ID

NCT04736758

Start Date

January 8 2021

End Date

December 18 2021

Last Update

July 26 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China, 330006